Soleno Therapeutics Inc (NASDAQ: SLNO) closed the day at $43.54, down -7.10% from its previous close of $46.87. The stock traded 5.39 million shares during the session, hitting a high of $46.15 and a low of $42.11. Over the past 52 weeks, SLNO has ranged from $41.50 to $90.32. Its 50-day moving average is -30.57%, while the 200-day moving average sits at -35.11%, highlighting recent volatility.
Key Ratios and Valuation Metrics
SLNO shows strong liquidity with a Quick Ratio of 15.88 and a Current Ratio of 16.08. The company carries minimal debt, with both Debt-to-Equity and Long-Term Debt-to-Equity ratios at 0.11. With a market capitalization of $2.34B and an enterprise value of $1.89B, the stock trades at a TTM Price-to-Sales ratio of 23.70 and a Price-to-Book ratio of 4.73. Enterprise Value per Revenue is 19.17, while EV/EBITDA is -23.0, reflecting the high-growth biotech profile.
Analyst Ratings and Price Targets
Analyst sentiment remains bullish despite recent volatility. Goldman Sachs initiated coverage on October 7, 2025, with a Buy rating and a target of $125. Wells Fargo followed on August 20, 2025, giving SLNO an Overweight rating and a $123 target. TD Cowen began tracking the stock on June 23, 2025, assigning a Buy rating and a $110 target.
Insider Activity
Insider moves signal confidence in SLNO’s long-term potential. Abingworth Bioventures VII LP recently acquired 1,347,522 shares at $82.15 per share on August 11, 2025. Officer Patricia Hirano purchased 3,830 shares at $82.76 on July 1, 2025, and now holds 13,206 shares.
Shares Statistics and Short Interest
SLNO trades an average of 1.99M shares per day over three months and 2.33M shares over the past 10 days. There are 53.70M shares outstanding, with a float of 46.01M. Insiders own 13.42%, while institutions hold a substantial 98.75% stake. Short interest stands at 8.44M shares, with a short ratio of 4.24 and a Short % of Float at 18.12%, reflecting significant bearish pressure.
Earnings Estimates
Analysts are cautiously optimistic. For the next quarter, consensus EPS is $0.35, with a range from -$0.34 to $0.88. The fiscal current-year EPS is expected to average $0.21, with estimates between $0.20 and $0.22. Looking ahead, next year’s EPS is projected at $2.95, with a wide analyst range of $1.01 to $5.78.
Revenue Estimates
Revenue expectations reflect strong growth potential. Analysts estimate $78.2M for the next quarter, ranging from $44.32M to $108.18M. For the next fiscal year, 11 analysts project $414.05M in revenue, with a high estimate of $563M and a low estimate of $252.18M.